p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells

Protein and Cell

Volumn 5, Issue 3, 2014, Pages 224-234

  Guo, Xiao Xi ^a,b   Li, Yang ^a   Sun, Chao ^a   Jiang, Dan ^a   Lin, Ying Jia ^a   Jin, Feng Xie ^c   Lee, Seung Ki ^d   Jin, Ying Hua ^a  

^a JILIN UNIVERSITY   (China)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c DALIAN POLYTECHNIC UNIVERSITY   (China)

^d Seoul National University   (South Korea)

Author keywords

apoptosis; Fas; G Rh2; p53

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C'; FAS ANTIGEN; GINSENOSIDE RH 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAK; PROTEIN BAX; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, CD95; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; ENZYME ACTIVATION; GINSENOSIDES; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MITOCHONDRIA; PROTEIN TRANSPORT; RECEPTORS, DEATH DOMAIN; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84898601806     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-014-0027-2     Document Type: Article

References (41)

1. Andrews GA, Xi SC, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR (2004) Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26: 870-877.
2. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355-358.
3. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171.
4. Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5: 231-237.
5. Brown JM, Wilson G (2003) Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther 2: 477-490.
6. Cappello F, Bellafiore M, Palma A, Bucchieri F (2002) Defective apoptosis and tumorigenesis: role of p53 mutation and Fas/FasL system dysregulation. Eur J Histochem 46: 199-208.
7. de la Monte SM, Sohn YK, Wands JR (1997) Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152: 73-83.
8. Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and cancer. Oncogene 23: 2950-2966.
9. Embree-Ku M, Venturini D, Boekelheide K (2002) Fas is involved in the p53-dependent apoptotic response to ionizing radiation in mouse testis. Biol Reprod 66: 1456-1461.
10. Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V (2012) Role of apoptosis in disease. Aging 4: 330-349.
11. Galmarini CM, Galmarini FC (2003) Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Investig Drugs 4: 1416-1421.
12. Gaur U, Aggarwal BB (2003) Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66: 1403-1408.
13. Guo XX, Guo Q, Li Y, Lee SK, Wei XN, Jin YH (2012) Ginsenoside Rh2 induces human hepatoma cell apoptosis via Bax/Bak triggered cytochrome C release and caspase-9/caspase-8 activation. Int J Mol Sci 22: 15523-15535.
14. Ham YM, Chun KH, Choi JS, Kim DH, Lee SK (2003) SEK1-dependent JNK1 activation prolongs cell survival during G-Rh2-induced apoptosis. Biochem Biophys Res Commun 304: 358-364.
15. 2+-mediated c-Jun NH2-terminal kinase 1 activation in HeLa cells. J Pharmacol Exp Ther 319: 1276-1285.
16. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770-776.
17. Jin YH, Yoo KJ, Lee YH, Lee SK (2000) Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J Biol Chem 275: 30256-30263.
18. Kawamata H, Omotehara F, Nakashiro K, Uchida D, Shinagawa Y, Tachibana M, Imai Y, Fujimori T (2007) Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage. Int J Oncol 30: 1089-1097.
19. Kim YS, Jin SH (2004) Ginsenoside Rh2 induces apoptosis via activation of caspase-1 and -3 and up-regulation of Bax in human neuroblastoma. Arch Pharm Res 27: 834-839.
20. Kim YS, Jin SH, Lee YH, Park JD, Kim SI (2000) Differential expression of protein kinase C subtypes during Ginsenoside Rh2-induced apoptosis in SK-N-BE(2) and C6Bu-1 cells. Arch Pharm Res 23: 518-524.
21. Kim SY, Kim DH, Han SJ, Hyun JW, Kim HS (2007) Repression of matrix metalloproteinase gene expression by Ginsenoside Rh2 in human astroglioma cells. Biochem Pharmacol 74: 1642-1651.
22. Li Y, He K, Huang YH, Zheng DX, Gao C, Cui L, Jin YH (2010) Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells. Mol Carcinog 49: 630-640.
23. Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS, Du W (2011a) Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 301: 185-192.
24. Li Q, Li Y, Wang XY, Fang XX, He K, Guo XX, Zhan Z, Sun C, Jin YH (2011b) Co-treatment with Ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, Bax translocation, and cytochrome C release. Mol Carcinog 50: 760-769.
25. Liu FS (2009) Mechanisms of chemotherapeutic drug resistance in cancer therapy-a quick review. Taiwan J Obstet Gynecol 48: 239-244.
26. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045.
27. Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33: 29-55.
28. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708.
29. Odashima S, Ohta T, Kohno H, Matsuda T, Kitagawa I, Abe H, Arichi S (1985) Control of phenotypic expression of cultured B16 melanoma cells by plant glycosides. Cancer Res 45: 2781-2784.
30. Oh JI, Chun KH, Joo SH, Oh YT, Lee SK (2005) Caspase-3-dependent protein kinase C delta activity is required for the progression of Ginsenoside-Rh2-induced apoptosis in SK-HEP-1 cells. Cancer Lett 230: 228-238.
31. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-3040.
32. Peter ME, Legembre P, Barnhart BC (2005) Does CD95 have tumor promoting activities? Biochim Biophys Acta 1755: 25-36.
33. Schilling T, Schleithoff ES, Kairat A, Melino G, Stremmel W, Oren M, Krammer PH, Muller M (2009) Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem Biophys Res Commun 387: 399-404.
34. Strasser A, Jost PJ, Nagata S (2009) The many roles of FAS receptor signaling in the immune system. Immunity 30: 180-192.
35. Takahashi R (1997) Role of p53 tumor suppressor gene and Fas/Apo-1 in induction of apoptosis and differentiation of cancer cells. Leukemia 11: 3331-3333.
36. van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P (2002) The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 9: 1031-1042.
37. Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30: 87.
38. Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M, Guns ES (2006) Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J Urol 175: 1926-1931.
39. Yi JS, Choo HJ, Cho BR, Kim HM, Kim YN, Ham YM, Ko YG (2009) Ginsenoside Rh2 induces ligand-independent Fas activation via lipid raft disruption. Biochem Biophys Res Commun 385: 154-159.
40. Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M (2003) Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22: 5667-5676.
41. Zhou M, Gu L, Yeager AM, Findley HW (1998) Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 12: 1756-1763.